Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label extension

Related Keywords

National Institutes Of Health ,Maryland ,United States ,Utah ,Salt Lake City ,Rob Etherington ,Clene Nanomedicine ,Clene Inc ,Access Program ,Natural History Consortium ,Securities Exchange ,Linkedin ,National Institute Of Neurological Disorders ,Twitter ,University Of South Carolina ,Clene Nanomedicine Inc ,Columbia University ,Drug Administration ,Nasdaq ,Expanded Access Program ,Recent Operating ,National Institute ,Neurological Disorders ,National Institutes ,History Consortium ,Brain Target Engagement ,Multiple Sclerosis ,Investigational Nanomedicine ,Springer Nature ,Mechanism Underpinning ,Bioenergetic Metabolism Regulating Function ,Gold Nanocatalysts ,South Carolina ,Open Access ,Securities Exchange Act ,Securities Act ,Annual Report ,Quarterly Reports ,Ended December ,Initial Stockholders ,Region ,